Eculizumab

Paroxysmal nocturnal hemoglobinuria

Paroxysmal
Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterised by complement-induced intravascular hemolytic anemia (anemia due to destruction of red blood cells in the bloodstream), red urine (due to the appearance of hemoglobin in the urine) and thrombosis. PNH is the only hemolytic anemia caused by an acquired (rather than inherited) intrinsic defect in the cell membrane (deficiency of glycophosphatidylinositol leading to absence of protective proteins on the membrane)...

Eculizumab - List of case studies

End Stage Renal Disease

last week in Boston a novel approach using C5 inhibitor eculizumab in the prevention of acute humoral rejection in highly sensitized ... study we evaluated the efficacy of the C5 inhibitor eculizumab in the prevention of AHR. Methods . All patients had a ...

Drugs

E E7080 EGFR inhibitors EGFRinhibitors Eculizumab Efexor Efferalgan Elasto-compressive bandaging ...

Treatments

C-met inhibitors C4-5 fusion C5 inhibitor Eculizumab C5-6 and C6-7 discectomy and fusion CBT CCNU ...

JustAnswer.com